Y-mAbs Therapeutics, Inc.’s Post

NEW from #ASCO2024 | Evaluating JZP898, an IFN-α and #pembrolizumab in advanced #solidtumors 🎥 🇺🇸 Meredith McKean, MD, MPH, Sarah Cannon Research Institute, shares findings from a Phase I, first-in-human study (NCT06108050) of JZP898, a conditionally activated prodrug of interferon alpha (IFN-α), alone or combined with #pembrolizumab in patients with advanced or #metastatic #solidtumors 🌟 The study aims to determine the maximum tolerated dose, safety, tolerability, #pharmacokinetics, and preliminary #antitumor activity 🌟 The combination is designed to enhance antitumor effects while minimizing systemic toxicity 🌟 Primary endpoints include dose-limiting toxicities and objective response rate, with secondary endpoints covering pharmacokinetics and overall survival Learn more 👉 https://lnkd.in/gzjRxJY7 #VJOncology #Oncologynews

Choosing the RIGHT model for your preclinical Immuno-Oncology and Oncology studies is crucial to accelerating your research. Download our Quick Guide comparing Syngeneic & Humanized Mouse Models and learn how to weigh the benefits and challenges you face when working with these models for oncology research. Learn More: https://hubs.li/Q02dkSqj0 #OncologyResearch #CancerResearch #ImmunoOncology #Humanized #Syngeneic

The phase II GMMG-CONCEPT trial showcases the Isa-KRD combination (isatuximab, carfilzomib, lenalidomide, and dexamethasone) as a potent initial treatment option for newly diagnosed high-risk multiple myeloma, achieving deep remissions. This regimen sets the stage for further comparison with treatments like D-RVCD (daratumumab, cyclophosphamide, bortezomib, lenalidomide, dexamethasone) and Dara-KRD (daratumumab, carfilzomib, lenalidomide, dexamethasone) in future research. The study was selected by Dr. Erika Lerch, one of the Oncology Compass Scientific Leaders, and can be found here: https://lnkd.in/da9Rt7gt #multiplemyeloma #oncology

Small Contribution in the world of oncology care has just been published! newly released book chapter titled "Somatic Mutations: Pharmacogenomic in Oncology Care." Dive into the world of cutting-edge research and explore the intricate relationship between somatic mutations and pharmacogenomics. Our chapter delves into the latest advancements that promise to revolutionize oncology care. #OncologyCare #ResearchMilestone #Pharmacogenomics #SomaticMutations #MedicalBreakthroughshttps https://lnkd.in/gp4HAiQa

Understanding the latest trends in metastatic breast cancer (mBC) treatment is vital for oncology pharmacists. Ryan Haumschild PharmD, MS, MBA, CPEL; Frank Scimeca, PharmD, MBA, BCOP; Heather Moore, PharmD, BCOP, CPP; and Britny Brown, PharmD, BCOP, engaged in a valuable discussion covering various topics such as the clinical impact of mBC, FDA-approved CDK4/6 inhibitors in personalized treatment, evaluating medication toxicity profiles, and more! Gain expert perspectives in the must-watch Peer Exchange episodes. Tune in here: https://bit.ly/4by3nXj.

New Blog: "Revolutionizing Oncology Research: The Rise of Decentralized Clinical Trials (DCTs)." Read more below. 🔬 At OneGlobal Trinity M Consulting, LLC, we are committed to advancing the use of DCTs to bring innovative cancer treatments to patients more efficiently and effectively. By embracing the decentralized model, we can make significant strides in oncology research, ultimately leading to better patient outcomes and accelerated development of new therapies. 👉 Contact us to learn more about our Clinical Trial Services and Solutions. #trinitymconsulting #globalconsulting #CRO #clinicaltrials #decentralizedtrials #oncology https://lnkd.in/eP9pKZkG

What does pharmacogenomics (PGx) in the oncology landscape look like today? Physicians and pharmacists are at the forefront of advancing the utilization of PGx testing in oncology. (Read more from OneOme's Ghada Elnashar, PharmD, MS and the Michigan State Medical Society at the link below) https://lnkd.in/gBDKgEuj #oncology #precisionmedicine #PGx #personalizedmedicine

We were thrilled today to present at the American Society of Clinical Oncology (ASCO) Annual Meeting. Two poster presentations spotlighted clinical trial data for Black Diamond’s #EGFR inhibitor BDTX-1535 in patients with recurrent #glioblastoma (GBM). These data were from a Phase 1 dose-escalation trial and a “window of opportunity” (Phase 0/1 “Trigger”) Investigator Sponsored Trial at the Ivy Brain Tumor Center.   Results demonstrated a favorable safety and tolerability profile and encouraging anti-tumor activity and duration of treatment. BDTX-1535 was also shown to achieve clinically meaningful drug levels in brain tumor tissue. Read more: https://lnkd.in/epsPKu_c View the posters here: https://lnkd.in/e3JeikQf   #ASCO2024 #GBM #oncology #biotech #healthcare #innovation

Today we reflect on the recent news highlighting the competitive landscapes within #ProstateCancer and #BreastCancers, as reported by Fierce Pharma. As evidenced throughout the article, Eli Lilly and Company and Novartis are both key players within these spaces. Our Heatmap analysis shows the landscape of ongoing clinical trials in metastatic castration-resistant prostate cancer (mCRPC). We see that both Eli Lilly and Novartis are active players within this highly competitive space, underscoring their commitment to advancing patient care. . . . . #ProstateCancer #BreastCancer #EliLilly #Novartis #ClinicalTrialsAI #mCRPC #CancerResearch #lifescienceAI #PharmaAI

🎉 Great news! Stemline Therapeutics, a Menarini Group company, has achieved a breakthrough with the FDA approval of ORSERDU™, a pioneering treatment for ER+, HER2- advanced/metastatic breast cancer patients with ESR1 mutations. See how we're lighting up the streets with their message using an LED digital billboard! Visit BulldogBillboards.com to learn more. #DigitalBillboardAdvertising #MarketingSuccess #InnovativeTherapy #CancerCare #FDAApproval #MedicalBreakthrough #HealthcareMarketing #TargetedTreatment #AdvertisingStrategy #StemlineTherapeutics